News >

Frontline Pembrolizumab Receives FDA Priority Review in Melanoma

Jason M. Broderick @jasoncology
Published: Tuesday, Aug 18, 2015

Dr. Roger Perlmutter

Roger M. Perlmutter, MD, PhD

The FDA has granted a priority review to pembrolizumab (Keytruda) as a frontline treatment for patients with advanced melanoma, according to Merck, the manufacturer of the anti–PD-1 therapy. A final decision is scheduled from the FDA by December 19, 2015.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication